Research Progress on Concurrent Surgical Approaches in the Treatment of Benign Prostatic Hyperplasia (BPH)

Xijun Liu; Xiangyang Zeng

doi:10.54097/dp6b1942

Authors

Xijun Liu
Xiangyang Zeng

DOI:

https://doi.org/10.54097/dp6b1942

Keywords:

Benign Prostatic Hyperplasia, Prostate Biopsy, 1470 nm Laser Surgery, Concurrent Surgery

Abstract

Benign prostatic hyperplasia (BPH) is an age-related non-cancerous condition, affecting approximately 50% of men over the age of 50, with the prevalence rising to over 80% in men over 80 years old. Elevated prostate-specific antigen (PSA) levels are commonly indicative of prostate diseases such as BPH or prostate cancer. In patients with multiple comorbidities and a limited life expectancy, even if prostate cancer is diagnosed, they may not be candidates for radical surgery. Therefore, a treatment approach that can both diagnose and relieve lower urinary tract obstruction is needed. Performing prostate biopsy and surgical treatment concurrently allows for both diagnosis and therapy in a single procedure, reducing the risks and recovery time associated with multiple surgeries, while enhancing the patient’s treatment experience and satisfaction. This article aims to explore the efficacy and safety of concurrent prostate biopsy and 1470 nm laser surgery.

Downloads

Download data is not yet available.

References

[1] Shen, X. (2018). Ethnic differences in prostate enlargement-related indicators among Han, Hui, and Tibetan populations in Qinghai (Master's thesis, Qinghai University).

[2] Fu, Q., Han, B., Liu, Z., & Ge, J. (2022). Expert consensus on prostate biopsy. Chinese Journal of Andrology, 28(5), 462–470.

[3] Xiang, J., Yan, H., Li, J., Wang, X., Chen, H., & Zheng, X. (2019). Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis. World journal of surgical oncology, 17(1), 31.

[4] Pradere, B., Veeratterapillay, R., Dimitropoulos, K., Yuan, Y., Omar, M. I., MacLennan, S., Cai, T., Bruyère, F., Bartoletti, R., Köves, B., Wagenlehner, F., Bonkat, G., & Pilatz, A. (2021). Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis. The Journal of urology, 205(3), 653–663.

[5] Grummet, J., Gorin, M. A., Popert, R., O'Brien, T., Lamb, A. D., Hadaschik, B., Radtke, J. P., Wagenlehner, F., Baco, E., Moore, C. M., Emberton, M., George, A. K., Davis, J. W., Szabo, R. J., Buckley, R., Loblaw, A., Allaway, M., Kastner, C., Briers, E., Royce, P. L., … Woo, H. H. (2020). "TREXIT 2020": why the time to abandon transrectal prostate biopsy starts now. Prostate cancer and prostatic diseases, 23(1), 62–65.

[6] Hodge, K. K., McNeal, J. E., Terris, M. K., & Stamey, T. A. (1989). Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. The Journal of urology, 142(1), 71–75.

[7] Yang, L. B., Wang, P. S., Li, F. P., Wang, Y. B., & Hou, Y. C. (2015). Comparison of the 6-needle, 10-needle, and 12-needle methods for ultrasound-guided transrectal prostate biopsy in the diagnosis of prostate cancer. Chinese Journal of Geriatrics, 06, 1578-1580.

[8] Wu, W. W., Lü, C., & Liu, Z. X. (2020). Comparison of diagnostic efficacy and complications of 16G and 18G needles for ultrasound-guided transrectal prostate biopsy in the diagnosis of prostate cancer. Chinese Journal of Andrology, 01, 31-35.

[9] Chen, X., Li, W., & Liu, J. L. (2013). Clinical comparison of 5-zone 13-core and 4-zone 10-core prostate biopsy for diagnosing prostate cancer. Journal of Modern Integrated Traditional Chinese and Western Medicine, 24, 2653-2654.

[10] Hwang, S. I., & Lee, H. J. (2019). Comparison of the diagnostic yield of various systematic randomized prostate biopsy protocols using prostate phantoms made of devil's tongue jelly. Ultrasonography (Seoul, Korea), 38(1), 44–49.

[11] Qian, G. Q., Xu, Q. Z., & Qian, Y. F. (2024). Diagnostic value of biomarkers combined with mp-MRI quantitative parameters for prostate cancer. Chinese Journal of Gerontology, 21, 5169-5172.

[12] Engels, R. R., Israël, B., Padhani, A. R., & Barentsz, J. O. (2020). Multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer: what urologists need to know. Part 1: acquisition. European urology, 77(4), 457-468.

[13] Park, B. K., Park, J. W., Park, S. Y., Kim, C. K., Lee, H. M., Jeon, S. S., Seo, S. I., Jeong, B. C., & Choi, H. Y. (2011). Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR. American journal of roentgenology, 197(5), W876–W881.

[14] Haffner, J., Lemaitre, L., Puech, P., Haber, G. P., Leroy, X., Jones, J. S., & Villers, A. (2011). Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU international, 108(8 Pt 2), E171–E178.

[15] Chen, Y. C., Liu, H. Q., Liu, Y. Q., Wang, J. W., & Tao, L. S. (2024). Application value of artificial intelligence-magnetic resonance imaging geometric model in transperineal prostate targeted biopsy. Journal of Urological Surgery (Electronic Edition), 03, 49-53.

[16] Elshal, A. M., El-Assmy, A., Mekkawy, R., Taha, D. E., El-Nahas, A. R., Laymon, M., El-Kappany, H., & Ibrahiem, E. H. (2017). Prospective controlled assessment of men's sexual function changes following Holmium laser enucleation of the prostate for treatment of benign prostate hyperplasia. International urology and nephrology, 49(10), 1741–1749.

[17] Yang, G. S., Chen, B. T., & Li, H. H. (2017). Application, innovation, and optimization of laser treatment for benign prostatic hyperplasia in China. Journal of Clinical Urology, 04, 245-249.

[18] Ye, P., & Cheng, F. (2019). Advances in minimally invasive treatment for benign prostatic hyperplasia. Medical Review, 05, 957-962.

[19] Wang, Y., Jia, Z., & Xu, Y. (2023). Laser treatment of benign prostatic hyperplasia. Chinese Journal of Clinical Doctors, 09, 1022-1024.

[20] Jiang, D., Xiao, C., Pang, J., Zhang, H., Mao, Y., & Gao, X. (2017). 1470 nm laser enucleation of the prostate for the treatment of benign prostatic hyperplasia. Chinese Journal of Laparoscopic Urology, Electronic Edition, 01, 4-8.

[21] Yin, Z., & Liu, Y. (2019). Transurethral resection of the prostate versus 1470 nm semiconductor laser vaporization for the treatment of benign prostatic hyperplasia. Chinese Journal of Sexual Science, 03, 25-28.

[22] Yu, M., & Tian, Z. (2019). Clinical research progress on laser treatment of benign prostatic hyperplasia. China Urban and Rural Enterprise Health, 07, 89-92.

[23] Chai, S. (2021). Efficacy analysis of transurethral prostate column water balloon dilation versus prostate resection in the treatment of small volume benign prostatic hyperplasia (Master’s thesis, North China University of Science and Technology).

[24] Liu, J., Mao, C., Li, J., & Guan, X. (2022). Efficacy analysis of 1470 nm laser selective prostate adenoma enucleation in the treatment of BPH patients.

[25] Xue, X., Huang, J., & Zhao, Y. (2020). Efficacy analysis of transurethral holmium laser enucleation for BPH patients with a history of prostate biopsy.

[26] Jia, Y., Zhou, G., & Liu, C. (2023). Impact of transperineal prostate biopsy on the safety and efficacy of HoLEP performed in the short term.